CD138 CAR-T therapy for relapsed /refractory multiple myeloma

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026351

Enrollment

Unknown

Registered

2019-10-01

Start date

2019-10-01

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B cell malignancies

Interventions

single arm:CD138 CAR-T treatment

Eligibility

Sex/Gender

All

Age

5 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. CD138 positive; 2. Relapsed/refractory; 3. More than 3 moths of survival time.

Exclusion criteria

Exclusion criteria: 1. Infection; 2. HIV positive; 3. Pregnancy.

Design outcomes

Primary

Measure	Time frame
overall survival rate;CRS rate;	—

Secondary

Measure	Time frame
overall survival rate;overall survival rate;infection rate;pancytopenia rate;	—

Countries

China

Contacts

Public ContactHe Huang

The First Affiliated Hospital, School of Medicine, Zhejiang University

huanghe@zju.edu.cn+86 13605714822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026